Bank of America has increased its price target on Apple Inc (NASDAQ:AAPL, ETR:APC), driven by confidence in a robust multi-year iPhone upgrade cycle.
Bank of America's analysts believe that two key factors will drive more customers to upgrade their iPhones in the coming years: an aging installed base (all the iPhones that have been sold and are actively being used by consumers) and promising generative AI features.
Manchester United Plc (NYSE:MANU) shares could be a big winner, reckon analysts at Jefferies, thanks to new management off the pitch.
The US investment bank issued a 'buy' rating based on a share price target of $26.00 versus the stock currently priced at $15.94, suggesting potential upside of 63%.
Haleon PLC (LSE:HLN, NYSE:HLN) first half/second quarter results on 1 August should be the last of ‘noise and volatility’ this year, suggests broker Jefferies.
From here on, it should be a normalised base of sales says the US bank, which expects volumes and product mix to underline it can be a 4-6% organic growth business.
Ecora Resources PLC (LSE:ECOR, TSX:ECOR, OTCQX:ECRAF) results this year might come in ahead of forecasts after an update from the owners of its Kestrel royalty in Australia, according to analysts at Panmure Liberum.
The royalty group indicated that Kestrel’s result would be first-half loaded, with income of US$40.8 million compared to Panmure’s full-year estimate of US$36 million.
Ilika PLC (AIM:IKA, OTCQX:ILIKF) saw its target price raised by Panmure Liberum after the solid-state battery developer published annual results today.
Panmure Liberum said it was a year of considerable progress for Ilika including first customer shipments of Stereax [medical] batteries from its UK pilot manufacturing facility and achieving D4 design freeze and Li-ion energy density parity in its Goliath [auto] prototypes.
Galliford Try Holdings PLC (LSE:GFRD) shares jumped by 7% as a post-close trading statement indicated revenue and pretax profit above the consensus range, helped by more normal trading conditions and the peak in AMP7 water sector work.
Based on the update, broker Panmure Liberum has increased what it said were already top-of-the-range estimates by 3% and 2% for 2024 and 2025
Shares in Faron Pharmaceuticals Limited (AIM:FARN) jumped almost 17% in early trading after receiving "very positive" feedback from the US Food & Drug Administration on the design of its phase III clinical trial for bexmarilimab, a treatment for myelodysplastic syndrome, a type of bone marrow cancer.
The FDA's feedback could streamline the development process, targeting newly diagnosed high-risk patients and eliminating the need for a separate study for resistant cases.